ProPhase Labs (PRPH) said late Thursday it priced an underwritten offering of 4.17 million shares of its common stock, targeting gross proceeds of about $3 million.
Shares slumped past 45%, with intraday trading volume at over 2.1 million compared with a daily average of about 34,000.
Evolent Health (EVH) shares plunged amid heavy trading after Truist Securities cut its price target on the company's stock following Q3 results that fell short of market expectations.
Oppenheimer also adjusted Evolent's price objective to $34 from $45 while maintaining its outperform rating.
Shares of Evolent sank 43% as intraday trading volume jumped to more than 14.4 million versus a daily average of about 2.1 million.
Maravai Lifesciences (MRVI) said late Thursday it agreed to buy Officinae Bio's DNA and RNA business. Financial terms of the deal were not disclosed.
Shares of Maravai slumped 39% as intraday trading volume climbed to over 8.5 million from the stock's daily average of about 1.9 million.
Price: 0.78, Change: -0.65, Percent Change: -45.24
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。